Serum CircCSPP1 is Correlated with the Occurrence and Severity of NAFLD in a Chinese Population

Abstract

The relationship between serum circCSPP1, circNIPSNAP3A, or circRFX8 and the occurrence and severity of non-alcoholic fatty liver disease (NAFLD) has yet to be fully elucidated. A total of 494 participants were divided into NAFLD and control groups, and clinical data, including demographic, physiological and biochemical parameters, were collected. Serum levels of circCSPP1, circNIPSNAP3A, and circRFX8 were measured using quantitative real-time PCR, and the severity of NAFLD was assessed by ultrasonography and quantitative computed tomography. The NAFLD group exhibited significantly higher levels of serum circCSPP1 compared to the control group (p=0.04). CircCSPP1 is significantly and independently associated with NAFLD. Participants with high serum circCSPP1 levels (>66th percentile) had a greater prevalence of mild and advanced NAFLD, as well as higher triglyceride levels, compared to those with low circCSPP1 levels (<33rd percentile) (p<0.05 for all). No significant correlations were observed between circNIPSNAP3A or circRFX8 and the occurrence or severity of NAFLD. These findings suggest that serum circCSPP1 is associated with the occurrence and severity of NAFLD, potentially mediated by hypertriglyceridemia.

Keywords

non-alcoholic fatty liver disease - circRNA - circCSPP1 - circNIPSNAP3A - circRFX8

Publication History

Received: 17 May 2023

Accepted after revision: 23 January 2025

Article published online:
06 March 2025

• References

• 1 Younossi ZM, Golabi P, Paik JM. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-1347
• 2 Wong VW, Ekstedt M, Wong GLH. et al. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol 2023; 79: 842-852
• 3 Paik JM, Henry L, Younossi Y. et al. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun 2023; 7: e0251
• 4 Scapaticci S, DʼAdamo E, Mohn A. et al. Non-alcoholic fatty liver disease in obese youth with insulin resistance and type 2 diabetes. Front Endocrinol (Lausanne) 2021; 12: 639548
• 5 Hrncir T, Hrncirova L, Kverka M. et al. Gut microbiota and NAFLD: pathogenetic mechanisms, microbiota signatures, and therapeutic interventions. Microorganisms 2021; 9: 957
• 6 Zhou WY, Cai ZR, Liu J. et al. Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer 2020; 19: 172
• 7 Zhou J, Li W, Chi X. et al. Inhibition of mmu_circ_0009303 improves metabolic dysfunction-associated steatotic liver disease by regulating lipid metabolism and oxidative stress. Endocr J 2025; 72: 79-91
• 8 Wu LF, Zhou ZJ, Zeng YH. et al. Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression. Am J Physiol Gastrointest Liver Physiol 2024; 327: G485-G498
• 9 Zailaie SA, Khoja BB, Siddiqui JJ. et al. Investigating the role of non-coding RNA in non-alcoholic fatty liver disease. Noncoding. RNA 2024; 10: 10
• 10 Yepmo M, Potier JP, Pinget M. et al. Discussing the role of circular RNA in the pathogenesis of non-alcoholic fatty liver disease and its complications. Front Endocrinol (Lausanne) 2022; 13: 1035159
• 11 Wang G, Tong J, Li Y. et al. Overview of circRNAs roles and mechanisms in liver fibrosis. Biomolecules 2023; 13: 940
• 12 Wei L, Liu L, Bai M. et al. CircRNAs: versatile players and new targets in organ fibrosis. Cell Commun Signal 2023; 21: 90
• 13 Shamsan E, Almezgagi M, Gamah M. et al. The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review. Front Med (Lausanne) 2024; 11: 1389329
• 14 Wang X, Nie H, Su M. et al. Serum circNIPSNAP3A is associated with metabolic disorders, atherosclerosis and severity of coronary artery disease in a Chinese population. Tohoku J Exp Med 2024; 263: 123-131
• 15 Chirichella M, Bianchi N, Džafo E. et al. RFX transcription factors control a miR-150/PDAP1 axis that restrains the proliferation of human T cells. PLoS Biol 2022; 20: e3001538
• 16 Harris HK, Nakayama T, Lai J. et al. Disruption of RFX family transcription factors causes autism, attention-deficit/hyperactivity disorder, intellectual disability, and dysregulated behavior. Genet Med 2021; 23: 1028-1040
• 17 Zhang J, Lou Z, Zheng Y. et al. CircRNA as an Achilles heel of cancer: characterization, biomarker and therapeutic modalities. J Transl Med 2024; 22: 752
• 18 Verduci L, Tarcitano E, Strano S. et al. CircRNAs: role in human diseases and potential use as biomarkers. Cell Death Dis 2021; 12: 468
• 19 Xie Y, Cao Y, Guo XY. et al. Profile analysis and functional modeling identify circular RNAs in nonalcoholic fatty liver disease as regulators of hepatic lipid metabolism. Front Genet 2022; 13: 884037
• 20 Li J, Qi J, Tang Y. et al. A nanodrug system overexpressed circRNA_0001805 alleviates nonalcoholic fatty liver disease via miR-106a-5p/miR-320a and ABCA1/CPT1 axis. J Nanobiotechnol 2021; 19: 363
• 21 Wang J, Qi J, Tang Y. et al. Circular RNA circCSPP1 promotes the occurrence and development of colon cancer by sponging miR-431 and regulating ROCK1 and ZEB1. J Transl Med 2022; 20: 58
• 22 Huang H, Lee SH, Sousa-Lima I. et al. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition. J Clin Invest 2018; 128: 5335-5350
• 23 Chen X, Tan XR, Li SJ. et al. LncRNA NEAT1 promotes hepatic lipid accumulation via regulating miR-146a-5p/ROCK1 in nonalcoholic fatty liver disease. Life Sci 2019; 235: 116829
• 24 Guo B, Cheng Y, Lao L. et al. LncRNA HOTAIR regulates the lipid accumulation in non-alcoholic fatty liver disease via miR-130b-3p/ROCK1 axis. Cell Signal 2022; 90: 110190
• 25 Chen X, Tan QQ, Tan XR. et al. Circ_0057558 promotes nonalcoholic fatty liver disease by regulating ROCK1/AMPK signaling through targeting miR-206. Cell Death Dis 2021; 12: 809
• 26 Zaky YA, Rashad MW, Zaater MA. et al. Discovery of dual rho-associated protein kinase 1 (ROCK1)/apoptosis signal-regulating kinase 1 (ASK1) inhibitors as a novel approach for non-alcoholic steatohepatitis (NASH) treatment. BMC Chem 2024; 18: 2
• 27 Lu J, Zhong C, Luo J. et al. HnRNP-L-regulated circCSPP1/miR-520h/EGR1 axis modulates autophagy and promotes progression in prostate cancer. Mol Ther Nucleic Acids 2021; 26: 927-944
• 28 Guo Y, Miao X, Sun X. et al. Zinc finger transcription factor Egf1 promotes non-alcoholic fatty liver disease. JHEP Rep 2023; 5: 100724
• 29 Sharma M, Urano F, Jaeschke A. Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. J Hepatol 2012; 56: 192-198
• 30 Zhang D, Yang X, Luo Q. et al. Circular RNA CSPP1 motivates renal cell carcinoma carcinogenesis and the Warburg effect by targeting RAC1 through microRNA-493-5p. Acta Biochim Pol 2023; 70: 693-701
• 31 Sugiaman-Trapman D, Vitezic M, Jouhilahti EM. et al. Characterization of the human RFX transcription factor family by regulatory and target gene analysis. BMC Genomics 2018; 19: 181
• 32 Zhang Y, Chen L, Zhu J. et al. Minor alleles of FTO rs9939609 and rs17817449 polymorphisms confer a higher risk of type 2 diabetes mellitus and dyslipidemia, but not coronary artery disease in a Chinese Han population. Front Endocrinol (Lausanne) 2023; 14: 1249070
• 33 Zhang Y, Li S, Nie H. et al. The rs17782313 polymorphism near MC4R gene confers a high risk of obesity and hyperglycemia, while PGC1α rs8192678 polymorphism is weakly correlated with glucometabolic disorder: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2023; 14: 1210455
• 34 Song Y, Wade H, Zhang B. et al. Polymorphisms of fat mass and obesity-associated gene in the pathogenesis of child and adolescent metabolic syndrome. Nutrients 2023; 15: 2643
• 35 Song Y, Raheel TM, Jia A. et al. rs10865710 polymorphism in PPARG promoter is associated with the severity of type 2 diabetes mellitus and coronary artery disease in a Chinese population. Postgrad Med J 2022; 98: 778-787
• 36 Li S, Zhang Y, Su W. et al. C Allele of the PPARδ+294T>C polymorphism confers a higher risk of hypercholesterolemia, but not obesity and insulin resistance: a systematic review and meta-analysis. Horm Metab Res 2023; 55: 355-366
• 37 Li S, He C, Nie H. et al. G Allele of the rs1801282 polymorphism in PPARγ gene confers an increased risk of obesity and hypercholesterolemia, while T allele of the rs3856806 polymorphism displays a protective role against dyslipidemia: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2022; 13: 919087
• 38 Song Y, Li S, He C. PPARγ Gene polymorphisms, metabolic disorders, and coronary artery disease. Front Cardiovasc Med 2022; 9: 808929
• 39 Su M, Song Y. The association between COMT Val158Met polymorphism and the post-traumatic stress disorder risk: a meta-analysis. Neuropsychobiology 2022; 81: 156-170
• 40 Su M, Jia A, He Y. et al. Associations of the polymorphisms in ADIPOQ with circulating levels of adiponectin and lipids: a meta-analysis. Horm Metab Res 2021; 53: 541-561